Better health protection from Buckman
19/09/2006
Memphis-based specialty chemical solutions for water treatment and the leather industry company Buckman Laboratories, Inc. has entered into an agreement with Salt Lake City-based biotech company OmniLytics, Inc. to pursue the commercialisation of bacteriophage-based products for E. coli, Salmonella and Listeria. Both firms are moving forward on a project that entails the external application of the bacteriophages to cattle, pigs, sheep and poultry livestock, both prior- and post-slaughter. This technology will reduce the threat of human enteric infections encountered through contamination associated with these pathogens.
Vice president of Buckman Laboratories Dean Didato stated, “This unique technology provides an innovative, yet very specific, means to address timely issues surrounding the reduction of pathogenic populations posing a threat to human health and welfare. The addition of this technology nicely complements recent advances that Buckman has made with respect to the use of non-traditional means to achieve similar results previously attained only by using synthetic chemistries.”
Share this story:
